NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00093-7355-56 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 15, 2006 | In Use | |
00781-2693-75 | 00781-2693 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
00781-2693-44 | 00781-2693 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
00093-7355-05 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 14, 2008 | In Use | |
00054-3177-57 | 00054-3177 | Dexamethasone | Dexamethasone | 0.5 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 1, 2007 | In Use | |
00002-6216-54 | 00002-6216 | Abemaciclib | Verzenio | 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct 6, 2017 | In Use | |
16729-0034-17 | 16729-0034 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 23, 2018 | In Use | ||
00781-2692-44 | 00781-2692 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
00781-2691-44 | 00781-2691 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
59746-0782-30 | 59746-0782 | Prednisone | Prednisone | 2.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 1, 2022 | In Use | |
00781-2321-51 | 00781-2321 | Aprepitant | Aprepitant | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 27, 2016 | In Use | |
00093-7355-01 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 15, 2006 | Aug 5, 2013 | In Use |
00054-3176-44 | 00054-3176 | Dexamethasone Intensol | Dexamethasone Intensol | 1.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 1, 1983 | In Use | |
00054-0497-14 | 00054-0497 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2020 | In Use | |
00054-0482-13 | 00054-0482 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Dec 7, 2021 | In Use | |
70771-1678-01 | 70771-1678 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
00054-0481-14 | 00054-0481 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2020 | In Use | |
00002-5337-63 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 5, 2020 | In Use | |
70518-3684-00 | 70518-3684 | Methylprednisolone sodium succinate | Methylprednisolone sodium succinate | 125.0 mg/2mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Mar 17, 2023 | In Use | |
00054-0481-13 | 00054-0481 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Feb 12, 2021 | In Use | |
51862-0682-01 | 51862-0682 | TAMOXIFEN CITRATE | SOLTAMOX | 20.0 mg/10mL | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jun 18, 2021 | In Use | ||
51862-0682-00 | 51862-0682 | TAMOXIFEN CITRATE | SOLTAMOX | 20.0 mg/10mL | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec 6, 2021 | In Use | ||
00093-7290-56 | 00093-7290 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Mar 28, 2014 | In Use | ||
00054-0480-14 | 00054-0480 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2020 | In Use | |
51862-0643-30 | 51862-0643 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug 27, 2021 | In Use |
Found 11120 results — Export these results